目的：探讨玻璃体腔注射阿柏西普治疗视网膜静脉阻塞(RVO)继发黄斑水肿的短期临床疗效。

方法：收集2019-05/10在我院门诊确诊为RVO继发黄斑水肿的患者24例24眼，均接受玻璃体腔注射阿柏西普治疗，分别于治疗前、治疗后1wk，1mo行视力和光学相干断层扫描血管成像(OCTA)黄斑区3mm×3mm范围检查，获得BCVA(LogMAR)、黄斑中心凹厚度(CMT)、黄斑区浅层毛细血管丛(SCP)血管密度、深层毛细血管丛(DCP)血管密度及中心凹无血管区(FAZ)面积、周长及非圆指数(AI)、拱环周围300μm(FD-300)范围血管密度。

结果：本组患者患眼治疗后1wk，1mo BCVA(0.44±0.29、0.34±0.27)均较治疗前(0.70±0.35)明显改善(均P<0.01)，但治疗后1wk与1mo BCVA无差异(P=0.260)； 治疗后1wk，1mo CMT(305.71±78.65、255.33±60.23μm)均较治疗前(542.42±189.02μm)明显下降(均P<0.001)，但治疗后1wk与1mo CMT无差异(P=0.161)； 治疗前后SCP、DCP及FD-300血管密度无明显差异(均P>0.05)，提示治疗前后浅层、深层视网膜毛细血管丛及FAZ周围血管密度均无明显改变； 治疗后1wk，1mo FAZ面积、周长均较治疗前增加，非圆指数较治疗前降低(均P<0.05)。

结论：玻璃体腔内注射阿柏西普治疗RVO继发黄斑水肿能够减轻黄斑水肿，改善视力，同时使FAZ形态更趋于规整，且未加重黄斑缺血。

METHODS: Totally 24 patients(24 eyes)with macular edema secondary to RVO confirmed by ophthalmic clinical examination received intravitreal injection of aflibercept from May to October in 2019 in hospital. Before and after the 1wk, 1mo treatment, all the eyes of the sick were examined with best corrected visual acuity(BCVA), optical coherence tomography angiography(3x3mm scanning range model)BCVA, central macular thickness(CMT), vascular density of superficial capillary plexus(SCP), vascular density of deep capillary plexus(DCP), and the area, perimeter and the roundness index in foveal avascular zone(FAZ)were observed.

RESULTS: Intravitreal injection of aflibercept for 1wk and 1mo, BCVA improved with the difference were statistically significant(P<0.05); The treatment for 1wk and 1mo, CMT decreased with the difference were statistically significant(P<0.001); There were no statistical difference for the vascular density of SCP,DCP and FD-300 before and after treatment 1wk, 1mo(P>0.05), and it revealed there was no obvious change for vascular density of SCP,DCP and FD-300(All P>0.05); The area and perimeter of FAZ after treatment increased obviously, and the roundness index of FAZ decreased than before with the difference were statistically significant(P<0.05).

CONCLUSION: For macular edema secondary to RVO, eyesight improved and edema absorbed obviously with the intravitreal injection of aflibercept in short-term clinical observation. At the same time, FAZ become regular and macular ischemia wasn't aggravated after treatment.